Cargando…

Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis

The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and acute pancreatitis. Recent meta-analyses have reported conflicting findings. Therefore, we performed a meta-analysis to assess the risk of both pancreatic cancer and acute pancreatitis associated with t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinto, Lana C., Rados, Dimitris V., Barkan, Sabrina S., Leitão, Cristiane B., Gross, Jorge L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768864/ https://www.ncbi.nlm.nih.gov/pubmed/29335646 http://dx.doi.org/10.1038/s41598-017-19055-6

Ejemplares similares

Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis
por: Pinto, Lana C., et al.
Publicado: (2019)

Screening for coronary artery disease in patients with type 2 diabetes: a meta-analysis and trial sequential analysis
por: Rados, Dimitris V, et al.
Publicado: (2017)

The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
por: Varvaki Rados, Dimitris, et al.
Publicado: (2016)

Correction: The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
por: Rados, Dimitris Varvaki, et al.
Publicado: (2016)

Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis: A meta-analysis
por: Chen, Shimin, et al.
Publicado: (2017)

Potential linkage between dipeptidyl peptidase‐4 inhibitor use and the risk of pancreatitis/pancreatic cancer
por: Shirakawa, Jun, et al.
Publicado: (2020)

Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
por: Pinto, Lana C., et al.
Publicado: (2022)

Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
por: Pinto, Lana Catani, et al.
Publicado: (2015)

Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials
por: Rados, Dimitris Varvaki, et al.
Publicado: (2020)

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors
por: Yang, Tzu-Lin, et al.
Publicado: (2016)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan
por: Kubota, Sodai, et al.
Publicado: (2022)

Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis
por: Liu, Xin, et al.
Publicado: (2016)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Dipeptidyl Peptidase IV Inhibitor MK-0626 Attenuates Pancreatic Islet Injury in Tacrolimus-Induced Diabetic Rats
por: Jin, Long, et al.
Publicado: (2014)

Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
por: Kim, Mee Kyoung, et al.
Publicado: (2023)

Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor
por: Nojima, Hiroyuki, et al.
Publicado: (2016)

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials
por: Monami, Matteo, et al.
Publicado: (2011)

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
por: Salvo, Francesco, et al.
Publicado: (2016)

Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials
por: Fu, Jianying, et al.
Publicado: (2016)

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
por: Taisiia Pavlovna, Tuchina, et al.
Publicado: (2021)

Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis
por: Takahashi, Masahiro, et al.
Publicado: (2020)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
por: Shoombuatong, Watshara, et al.
Publicado: (2015)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
por: Yazbeck, R., et al.
Publicado: (2021)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022)

Computational Analysis of Gynura bicolor Bioactive Compounds as Dipeptidyl Peptidase-IV Inhibitor
por: Rozano, Lina, et al.
Publicado: (2017)

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study
por: Lai, Yun-Ju, et al.
Publicado: (2015)

Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors
por: Alanazi, Abdulrahman S.
Publicado: (2015)

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2018)

Effect of dipeptidyl peptidase-4 inhibitors inhibitor on cognitive dysfunction in diabetes: A protocol for systematic review and meta analysis
por: Liu, Shiyu, et al.
Publicado: (2020)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f2bvlqe19gfkjhhjkvhbbjd3k9